Related Experiment Video
Updated: May 15, 2026
10:11
Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
A focus on PD-L1 in human melanoma
Peter Hersey1, Stuart Gallagher
1Kolling Institute, Royal North Shore Hospital & Melanoma Institute of Australia, University of Sydney, New South Wales, Australia. peter.hersey@sydney.edu.au
Summary
BRAF V600 inhibitors are limited by resistance in melanoma treatment. This study investigates if resistance to BRAF inhibitors impacts melanoma
Area of Science:
- Oncology
- Cancer Research
- Immunology
Background:
- Metastatic melanoma treatment often involves BRAF V600 inhibitors.
- Acquired resistance to BRAF inhibitors limits their long-term efficacy.
- Combining BRAF inhibitors with immunotherapy is a potential strategy to overcome resistance.
Purpose of the Study:
- To determine if resistance to BRAF V600 inhibitors confers cross-resistance to immunotherapy in melanoma.
- To explore the mechanisms underlying potential combined resistance.
Main Methods:
- Utilizing melanoma cell lines with acquired resistance to BRAF inhibitors.
- Assessing the sensitivity of resistant cells to various immunotherapeutic agents.
- Investigating molecular alterations in resistant melanoma cells.
Main Results:
- Melanoma cells resistant to BRAF inhibitors may exhibit altered responses to immunotherapy.
- Specific molecular pathways may mediate cross-resistance.
- Understanding these mechanisms is crucial for optimizing combination therapies.
Conclusions:
- Acquisition of BRAF inhibitor resistance can impact the effectiveness of immunotherapy in melanoma.
- Further research is needed to develop strategies to overcome dual resistance.
- This has implications for designing more effective treatment regimens for metastatic melanoma.
